Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Valeant to acquire iNova
Under the terms of the agreement, Valeant will pay iNova shareholders A$625m ($623.39) upfront and up to an additional A$75m ($74.81) in potential milestones. Valeant Pharmaceuticals develops, manufactures
Under the terms of the agreement, Valeant will pay iNova shareholders A$625m ($623.39) upfront and up to an additional A$75m ($74.81) in potential milestones. Valeant Pharmaceuticals develops, manufactures
The deal is expected to strengthen Lupin’s presence in the Japanese market. Lupin president (Asia Pacific, Middle East, Africa and Latin America) Vinod Dhawan said the acquisition would
TNX-102 is a bedtime gelcap with very low dose cyclobenzaprine, which aids in faster and improved absorption as compared to conventional cyclobenzaprine products. The single-dose open-label randomised three-way-crossover
Eylea is a recombinant fusion protein, that binds VEGF-A and placental growth factor (PlGF) to inhibit the binding and activation of these cognate VEGF receptors. The recommended dose
The therapies include Onbrez Inhalation Capsules 150 mcg (indacaterol maleate) and the investigational drugs NVA237 (glycopyrronium bromide) and QVA149 (fixed-dose combination of indacaterol maleate and glycopyrronium bromide). NVA237and
The move indicates that in patients with unknown or negative Rearranged during Transfection (RET) mutation, a lower benefit should be considered prior to individual treatment decisions. Clinical data
MM-121 is a fully human monoclonal antibody that targets ErbB3, while erlotinib (Tarceva) is a small molecule directed at the epidermal growth factor receptor (EGFR). The study is
Sativex is also protected by a number of other patents related to different aspects of the product. GW chairman Geoffrey Guy said the grant of this patent is
Vitera’s solutions are believed to improve practice management and improve patient care which is why facilities from Connecticut, Florida, Kentucky, Nevada, Pennsylvania and Texas have adopted the Vitera
Under the partnership agreement, both the companies are delving into the technical details of the integration which will result into integration between the OnCore system for clinical research